Valerie Speirs

List of Publications by Year
in descending order

155	7,173	81743	62479
papers	citations	39 h-index	80 g-index

161	161	161	12480
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Choosing the right cell line for breast cancer research. Breast Cancer Research, 2011, 13, 215.	2.2	1,153
2	Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial. Journal of Clinical Oncology, 2008, 26, 1059-1065.	0.8	409
3	Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation. Nucleic Acids Research, 2012, 40, e82-e82.	6.5	356
4	Pan-cancer image-based detection of clinically actionable genetic alterations. Nature Cancer, 2020, 1, 789-799.	5.7	343
5	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Research, 2013, 15, R92.	2.2	320
6	Breast cancer cell lines: friend or foe?. Breast Cancer Research, 2003, 5, 89-95.	2.2	238
7	Nuclear and Cytoplasmic Expression of ERÎ²1, ERÎ²2, and ERÎ²5 Identifies Distinct Prognostic Outcome for Breast Cancer Patients. Clinical Cancer Research, 2008, 14, 5228-5235.	3.2	207
8	Reduced expression of oestrogen receptor ? in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. Journal of Pathology, 2003, 201, 213-220.	2.1	186
9	Phyto-oestrogens and breast cancer chemoprevention. Breast Cancer Research, 2004, 6, 119-27.	2.2	175
10	Relationship of Extreme Chromosomal Instability with Long-term Survival in a Retrospective Analysis of Primary Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2183-2194.	1.1	141
11	Metastatic-niche labelling reveals parenchymal cells with stem features. Nature, 2019, 572, 603-608.	13.7	139
12	In vivomodels in breast cancer research: progress, challenges and future directions. DMM Disease Models and Mechanisms, 2017, 10, 359-371.	1.2	131
13	The rising incidence of male breast cancer. Breast Cancer Research and Treatment, 2009, 115, 429-430.	1.1	130
14	Evaluation of seven oestrogen receptor ? antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue. Journal of Pathology, 2002, 197, 155-162.	2.1	129
15	Tumour cell-derived Wnt7a recruits and activates fibroblasts to promote tumour aggressiveness. Nature Communications, 2016, 7, 10305.	5.8	127
16	Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: Identification of interleukin-8 as a potential regulatory factor in breast tumours. , 1997, 72, 937-941.		122
17	A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences. Breast Cancer Research and Treatment, 2012, 133, 949-958.	1.1	119
18	Oestrogen receptor Î²: what it means for patients with breast cancer. Lancet Oncology, The, 2004, 5, 174-181.	5.1	116

#	Article	IF	Citations
19	Estrogen Receptor Î²1 Expression Is Regulated by miR-92 in Breast Cancer. Cancer Research, 2010, 70, 4778-4784.	0.4	107
20	Male breast carcinoma: increased awareness needed. Breast Cancer Research, 2011, 13, 219.	2.2	103
21	MiR-26b is down-regulated in carcinoma-associated fibroblasts from ER-positive breast cancers leading to enhanced cell migration and invasion. Journal of Pathology, 2013, 231, 388-399.	2.1	103
22	Clinical and functional significance of loss of caveolinâ€1 expression in breast cancerâ€associated fibroblasts. Journal of Pathology, 2012, 227, 490-498.	2.1	87
23	CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment. Journal of the National Cancer Institute, 2016, 108, .	3.0	75
24	Oestrogen receptor ? in breast cancer: good, bad or still too early to tell?. Journal of Pathology, 2002, 197, 143-147.	2.1	73
25	Genetic changes in breast cancer detected by comparative genomic hybridisation. , 2000, 86, 494-500.		69
26	Expression of alternatively spliced estrogen receptor alpha mRNAs is increased in breast cancer tissues. Journal of Steroid Biochemistry and Molecular Biology, 2001, 78, 459-469.	1.2	66
27	A Rac/Cdc42 exchange factor complex promotes formation of lateral filopodia and blood vessel lumen morphogenesis. Nature Communications, 2015, 6, 7286.	5.8	66
28	Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ. European Journal of Surgical Oncology, 2018, 44, 429-435.	0.5	62
29	Loss of CSMD1 expression is associated with high tumour grade and poor survival in invasive ductal breast carcinoma. Breast Cancer Research and Treatment, 2010, 121, 555-563.	1.1	60
30	Activity and gene expression of 17Î²-hydroxysteroid dehydrogenase type I in primary cultures of epithelial and stromal cells derived from normal and tumourous human breast tissue: the role of IL-8. Journal of Steroid Biochemistry and Molecular Biology, 1998, 67, 267-274.	1.2	57
31	Raman spectroscopy: current applications in breast cancer diagnosis, challenges and future prospects. British Journal of Cancer, 2022, 126, 1125-1139.	2.9	54
32	The practicalities of using tissue slices as preclinical organotypic breast cancer models. Journal of Clinical Pathology, 2013, 66, 253-255.	1.0	52
33	Characterisation of male breast cancer: a descriptive biomarker study from a large patient series. Scientific Reports, 2017, 7, 45293.	1.6	50
34	Identification of Wild-Type and Exon 5 Deletion Variants of Estrogen Receptor Î² in Normal Human Mammary Gland1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1601-1605.	1.8	49
35	CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploidâ€specific cancer cell death through autophagy induction. Journal of Pathology, 2012, 226, 482-494.	2.1	48
36	Insulin-like growth factor â€" Oestradiol crosstalk and mammary gland tumourigenesis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2013, 1836, 345-353.	3.3	46

#	Article	IF	Citations
37	A Multi-Centre Investigation Towards Reaching a Consensus on the Immunohistochemical Detection of ERÎ² in Archival Formalin-ï¬xed Paraffin Embedded Human Breast Tissue. Breast Cancer Research and Treatment, 2005, 92, 287-293.	1.1	45
38	Carcinoembryonic Antigen Cell Adhesion Molecule 6 Predicts Breast Cancer Recurrence following Adjuvant Tamoxifen. Clinical Cancer Research, 2008, 14, 405-411.	3.2	44
39	Differential response to phytoestrogens in endocrine sensitive and resistant breast cancer cellsin vitro. International Journal of Cancer, 2006, 119, 515-521.	2.3	43
40	The manufacture and assessment of tissue microarrays: suggestions and criteria for analysis, with breast cancer as an example. Journal of Clinical Pathology, 2013, 66, 169-177.	1.0	43
41	Male breast cancer: an update. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 85-93.	1.4	43
42	Pattern of expression of genes linked to epigenetic silencing in human breast cancerâ¨†. Human Pathology, 2006, 37, 989-999.	1.1	41
43	Constitutive co-expression of estrogen and progesterone receptor mRNA in human meningiomas by RT-PCR and response ofin vitro cell cultures to steroid hormones. , 1997, 72, 714-719.		36
44	Phosphorylation of Estrogen Receptor Î² at Serine 105 Is Associated with Good Prognosis in Breast Cancer. American Journal of Pathology, 2010, 177, 1079-1086.	1.9	35
45	The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer. Oncotarget, 2016, 7, 43188-43198.	0.8	35
46	Identification and validation of DOCK4 as a potential biomarker for risk of bone metastasis development in patients with early breast cancer. Journal of Pathology, 2019, 247, 381-391.	2.1	33
47	Expression of oestrogen receptor Î² isoforms is regulated by transcriptional and post-transcriptional mechanisms. Biochemical Journal, 2010, 429, 283-290.	1.7	32
48	Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis. Journal of Hematology and Oncology, 2015, 8, 53.	6.9	32
49	A NOVEL CELL ARRAY TECHNIQUE FOR HIGH-THROUGHPUT, CELL-BASED ANALYSIS. In Vitro Cellular and Developmental Biology - Animal, 2005, 41, 185.	0.7	31
50	ERÎ²1 Represses FOXM1 Expression through Targeting ERÎ± to Control Cell Proliferation in Breast Cancer. American Journal of Pathology, 2011, 179, 1148-1156.	1.9	31
51	Differential regulation of oestrogen receptor Î² isoforms by 5â€² untranslated regions in cancer. Journal of Cellular and Molecular Medicine, 2010, 14, 2172-2184.	1.6	30
52	Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation. Breast Cancer Research and Treatment, 2011, 127, 639-648.	1.1	30
53	Genetic events during the transformation of a tamoxifen-sensitive human breast cancer cell line into a drug-resistant clone. Cancer Genetics and Cytogenetics, 2001, 130, 166-172.	1.0	29
54	Threeâ€dimensional reconstruction of ductal carcinoma inÂsitu with virtual slides. Histopathology, 2015, 66, 966-973.	1.6	28

#	Article	IF	Citations
55	Development and characterisation of a 3D multi-cellularin vitromodel of normal human breast: a tool for cancer initiation studies. Oncotarget, 2015, 6, 13731-13741.	0.8	26
56	Obesity and male breast cancer: provocative parallels?. BMC Medicine, 2015, 13, 134.	2.3	26
57	Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series. Breast Cancer Research and Treatment, 2014, 148, 73-80.	1.1	24
58	Identification of Stage-Specific Breast Markers Using Quantitative Proteomics. Journal of Proteome Research, 2013, 12, 5696-5708.	1.8	23
59	The potential utility of geminin as a predictive biomarker in breast cancer. Breast Cancer Research and Treatment, 2014, 143, 91-98.	1.1	21
60	Differential Expression of MicroRNAs in Breast Cancers from Four Different Ethnicities. Pathobiology, 2018, 85, 220-226.	1.9	21
61	Down-Regulation of miR-92 in Breast Epithelial Cells and in Normal but Not Tumour Fibroblasts Contributes to Breast Carcinogenesis. PLoS ONE, 2015, 10, e0139698.	1.1	21
62	Current and Emerging 3D Models to Study Breast Cancer. Advances in Experimental Medicine and Biology, 2019, 1152, 413-427.	0.8	20
63	Preclinical models of glioblastoma: limitations of current models and the promise of new developments. Expert Reviews in Molecular Medicine, 2021, 23, e20.	1.6	20
64	A comparative study of genome-wide SNP, CGH microarray and protein expression analysis to explore genotypic and phenotypic mechanisms of acquired antiestrogen resistance in breast cancer. Breast Cancer Research and Treatment, 2008, 111, 55-63.	1.1	19
65	Lack of CD151/integrin Î±3Î²1 complex is predictive of poor outcome in node-negative lobular breast carcinoma: opposing roles of CD151 in invasive lobular and ductal breast cancers. British Journal of Cancer, 2015, 113, 1350-1357.	2.9	19
66	Loss of CSMD1 expression disrupts mammary duct formation while enhancing proliferation, migration and invasion. Oncology Reports, 2017, 38, 283-292.	1.2	19
67	Reflections on the upsurge of virtual cancer conferences during the COVID-19 pandemic. British Journal of Cancer, 2020, 123, 698-699.	2.9	19
68	Deregulation of IGF-binding proteins -2 and -5 contributes to the development of endocrine resistant breast cancerin vitro. Oncotarget, 2016, 7, 32129-32143.	0.8	19
69	A comparative study of cytokine gene transcripts in normal and malignant breast tissue and primary cell cultures derived from the same tissue samples. , 1996, 66, 551-556.		18
70	PSMD9 expression predicts radiotherapy response in breast cancer. Molecular Cancer, 2014, 13, 73.	7.9	18
71	The Sharing Experimental Animal Resources, Coordinating Holdings (SEARCH) Framework: Encouraging Reduction, Replacement, and Refinement in Animal Research. PLoS Biology, 2017, 15, e2000719.	2.6	18
72	Regulation of estrogen receptor Î²1 expression in breast cancer by epigenetic modification of the 5â€² regulatory region. International Journal of Oncology, 2013, 43, 2039-2045.	1.4	17

#	Article	IF	Citations
73	Androgen receptor and antiandrogen therapy in male breast cancer. Cancer Letters, 2015, 368, 20-25.	3.2	17
74	A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer. Clinical Cancer Research, 2017, 23, 2575-2583.	3.2	16
75	The evolving role of oestrogen receptor Î² in clinical breast cancer. Breast Cancer Research, 2008, 10, 111.	2.2	15
76	Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression. Scientific Reports, 2017, 7, 8078.	1.6	14
77	An Evaluation of Matrix-Containing and Humanised Matrix-Free 3-Dimensional Cell Culture Systems for Studying Breast Cancer. PLoS ONE, 2016, 11, e0157004.	1.1	14
78	RT-PCR DETECTION OF CYTOKINE TRANSCRIPTS IN A SERIES OF CULTURED HUMAN MENINGIOMAS. , 1996, 178, 442-446.		12
79	Investment biobankingâ€"increased returns from tissue samples. Nature Reviews Clinical Oncology, 2013, 10, 128-129.	12.5	12
80	Oestrogen receptor Î² (ERÎ²) regulates osteogenic differentiation of human dental pulp cells. Journal of Steroid Biochemistry and Molecular Biology, 2017, 174, 296-302.	1.2	12
81	Stanniocalcin 2 expression is associated with a favourable outcome in male breast cancer. Journal of Pathology: Clinical Research, 2018, 4, 241-249.	1.3	12
82	MicroRNA-495/TGF-Î²/FOXC1 axis regulates multidrug resistance in metaplastic breast cancer cells. Biochemical Pharmacology, 2021, 192, 114692.	2.0	12
83	The value of archival tissue blocks in understanding breast cancer biology. Journal of Clinical Pathology, 2014, 67, 272-275.	1.0	11
84	SEARCHBreast: a new resource to locate and share surplus archival material from breast cancer animal models to help address the 3Rs. Breast Cancer Research and Treatment, 2016, 156, 447-452.	1.1	11
85	Conditions of the male breast: Gynaecomastia and male breast cancer (Review). Molecular Medicine Reports, 2009, 3, 21-6.	1.1	10
86	Expression of regulators of mitotic fidelity are associated with intercellular heterogeneity and chromosomal instability in primary breast cancer. Breast Cancer Research and Treatment, 2014, 148, 221-229.	1.1	10
87	A Review of International Biobanks and Networks: Success Factors and Key Benchmarksâ€"A 10-Year Retrospective Review. Biopreservation and Biobanking, 2019, 17, 512-519.	0.5	10
88	Share surplus animal tissue. Nature, 2015, 522, 156-156.	13.7	9
89	Association between AXL, Hippo Transducers, and Survival Outcomes in Male Breast Cancer. Journal of Cellular Physiology, 2017, 232, 2246-2252.	2.0	9
90	Incidence of male breast cancer in Scotland over a twenty-five-year period (1992â€“2017). European Journal of Surgical Oncology, 2020, 46, 1546-1550.	0.5	9

#	Article	IF	Citations
91	Exploring the influence of rural residence on uptake of organized cancer screening â€“ A systematic review of international literature. Cancer Epidemiology, 2021, 74, 101995.	0.8	9
92	Interleukin-3: A putative protective factor against breast cancer which is secreted by male but not female breast fibroblasts. International Journal of Cancer, 1995, 61, 416-419.	2.3	8
93	Problems (and solutions) in the study of male breast cancer. Rare Tumors, 2010, 2, 78-78.	0.3	8
94	Epithelial-mesenchymal interactions in breast cancer: evidence for a role of nuclear localized Î²-catenin in carcinoma-associated fibroblasts. Histopathology, 2011, 59, 609-618.	1.6	8
95	Adding value to rare tissue samples donated to biobanks: characterisation of breast tissue and primary cell cultures obtained from a female-to-male transgender patient. Cell and Tissue Banking, 2015, 16, 27-34.	0.5	8
96	Clinical Importance of Estrogen Receptor Î² Isoforms in Breast Cancer. Journal of Clinical Oncology, 2008, 26, 5825-5825.	0.8	7
97	Estrogen receptor Î²: putting a positive into triple negative breast cancer?. Hormone Molecular Biology and Clinical Investigation, 2013, 16, 117-123.	0.3	7
98	SEARCHBreast Workshop Proceedings: 3D Modelling of Breast Cancer. ATLA Alternatives To Laboratory Animals, 2015, 43, 367-375.	0.7	7
99	Intracellular Flow Cytometric Analysis of Primary Cultured Breast Tumor Cells. Cancer Investigation, 2002, 20, 340-347.	0.6	6
100	Hormone receptors in defining breast cancer prognosisâ€”time for a rethink?. Nature Clinical Practice Oncology, 2007, 4, 204-205.	4.3	6
101	3-D Tissue Modelling and Virtual Pathology as New Approaches to Study Ductal Carcinoma In Situ. ATLA Alternatives To Laboratory Animals, 2015, 43, 377-383.	0.7	6
102	HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes. Scientific Reports, 2016, 6, 35121.	1.6	6
103	Advances in the development of improved animal-free models for use in breast cancer biomedical research. Biophysical Reviews, 2017, 9, 321-327.	1.5	6
104	Characterising the adipose-inflammatory microenvironment in male breast cancer. Endocrine-Related Cancer, 2018, 25, 773-781.	1.6	6
105	Analysis of the Clinical Advancements for BRCA-Related Malignancies Highlights the Lack of Treatment Evidence for BRCA-Positive Male Breast Cancer. Cancers, 2022, 14, 3175.	1.7	6
106	Identification of differentially expressed genes in matched formalinâ€fixed paraffinâ€embedded primary and metastatic melanoma tumor pairs. Pigment Cell and Melanoma Research, 2012, 25, 284-286.	1.5	5
107	Quality Considerations When Using Tissue Samples for Biomarker Studies in Cancer Research. Biomarker Insights, 2021, 16, 117727192110095.	1.0	5
108	The Estrogen Receptors Î±, Î², and Î²cx. Clinical Cancer Research, 2005, 11, 8222-8223.	3.2	4

#	Article	IF	Citations
109	Towards a-scan imaging via Ultrasonic Vibration Potential measurements. Nuclear Engineering and Design, 2011, 241, 1994-1997.	0.8	4
110	Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERÎ±-positive breast cancer. Exploration of Targeted Anti-tumor Therapy, 2020, 1, 355-371.	0.5	4
111	Gene expression of ERbeta isoforms in laser microdissected human breast cancers: implications for gene expression analyses. Cellular Oncology, 2009, 31, 467-73.	1.9	4
112	Wnt signalling in mammary carcinogenesis. Breast Cancer Research, 2002, 4, 1.	2.2	3
113	Steroid hormone receptor expression in breast cancer stroma. Breast Cancer Research and Treatment, 2014, 143, 605-607.	1.1	3
114	External validation of the ImmunoRatio image analysis application for ERÎ± determination in breast cancer. Journal of Clinical Pathology, 2014, 67, 72-75.	1.0	3
115	The Cellular and Molecular Pathology Biobanking Sample Quality Improvement Tool: A Guide for Improving the Quality of Tissue Collections for Biomedical Research and Clinical Trials in Cancer. Biopreservation and Biobanking, 2021, 19, 86-90.	0.5	3
116	A Global View of Breast Tissue Banking. Advances in Experimental Medicine and Biology, 2015, 864, 69-77.	0.8	3
117	Radiotherapy biobanking: current landscape, opportunities, challenges, and future aspirations. Journal of Pathology: Clinical Research, 2021, , .	1.3	3
118	Estrogen receptor regulation: donâ€™t forget translation. Breast Cancer Research and Treatment, 2010, 121, 251-252.	1.1	2
119	Investigating and critically appraising the expression and potential role of androgen receptor in breast carcinoma. Hormone Molecular Biology and Clinical Investigation, 2011, 7, 273-8.	0.3	2
120	Perspective: Not just for women. Nature, 2012, 485, S66-S66.	13.7	2
121	SEARCHBreast: a new online resource to make surplus material from in vivo models of breast cancer visible and accessible to researchers. Breast Cancer Research, 2016, 18, 59.	2.2	2
122	CIP2A expression predicts recurrences of tamoxifen-treated breast cancer. Tumor Biology, 2017, 39, 101042831772206.	0.8	2
123	Barriers to the release of human tissue for clinical trials research in the UK: a national survey of cellular pathology laboratories on behalf of the National Cancer Research Instituteâ€™s Cellular Molecular Pathology (CM-Path) initiative. Journal of Clinical Pathology, 2019, 72, 52-57.	1.0	2
124	BPA and risk assessment. Lancet Diabetes and Endocrinology,the, 2020, 8, 269.	5.5	2
125	A biobank perspective on use of tissue samples donated by trial participants. Lancet Oncology, The, 2022, 23, e205.	5.1	2
126	Estrogen receptor Î²â€”which one and where should we draw the line?. Human Pathology, 2006, 37, 498-498.	1.1	1

#	Article	IF	Citations
127	Role of miR-26b in carcinoma-associated fibroblasts and effect on migration and invasion of breast cancer epithelial cells. Lancet, The, 2014, 383, S103.	6.3	1
128	Modelling the Molecular Pathology of Breast Cancer Initiation. Molecular Pathology Library, 2015, , 39-50.	0.1	1
129	Introducing SEARCHBreast: a virtual resource to facilitate sharing of surplus animal material developed for breast cancer research. Npj Breast Cancer, 2016, 2, 16020.	2.3	1
130	Rho GTPase signaling and role of the Rac1 exchange factor DOCK4 in GBM invasion and vascular growth. Neuro-Oncology, 2018, 20, i17-i17.	0.6	1
131	Biobanking in radiotherapy trials â€" a challenge to the clinical research community. Nature Reviews Clinical Oncology, 2021, 18, 191-192.	12.5	1
132	Constitutive co-expression of estrogen and progesterone receptor mRNA in human meningiomas by RT-PCR and response of in vitro cell cultures to steroid hormones. , 0, .		1
133	Genetic changes in breast cancer detected by comparative genomic hybridisation. , 2000, 86, 494.		1
134	Treatment and outcomes from a large, prospective, national longitudinal cohort study of screen detected ductal carcinoma in situ (DCIS).. Journal of Clinical Oncology, 2016, 34, 1570-1570.	0.8	1
135	Abstract B127: Loss of miR-92 expression in breast epithelial cells is associated with cancer progression. , 2013, , .		1
136	Cytokine Expression in Normal and Neoplastic Breast Tissue. , 1995, , 101-102.		1
137	Labeling of a Mutant Estrogen Receptor with an Affimer in a Breast Cancer Cell Line. Biophysical Journal, 2022, , .	0.2	1
138	Introducing Viewpoints â€" Breast Cancer Research'snew style literature appraisal service. Breast Cancer Research, 2003, 5, 1.	2.2	0
139	Role of ERÎ² in Clinical Breast Cancer. Cancer Treatment and Research, 2009, 147, 1-20.	0.2	0
140	O-9 Loss of CSMD1 expression disrupts cell morphology and mammary duct formation while enhancing proliferation, migration and invasion. European Journal of Cancer, Supplement, 2010, 8, 4.	2.2	0
141	A comparative study of the prognostic role of KI67 and geminin in breast cancer. International Journal of Surgery, 2013, 11, 592.	1.1	0
142	The Molecular Pathology of Male Breast Cancer. Molecular Pathology Library, 2015, , 309-315.	0.1	0
143	SEARCHBreast: An online resource designed to increase the efficiency of using materials derived from breast cancer studies in animals. Journal of Pathology, 2016, 240, 120-120.	2.1	0
144	Management of breast cancer in an Asian man with post-traumatic stress disorder: a case report. Journal of Medical Case Reports, 2016, 10, 77.	0.4	0

#	Article	IF	Citations
145	Attitudes of female staff and students from two United Kingdom Medical Schools towards donating normal healthy breast tissue and blood samples for biomedical research. Breast Cancer Research and Treatment, 2017, 166, 651-652.	1.1	0
146	Variability In Plasma VEGF. Medicine and Science in Sports and Exercise, 2005, 37, S156.	0.2	0
147	Gene Expression of ERÎ² Isoforms in Laser Microdissected Human Breast Cancers: Implications for Gene Expression Analyses. Analytical Cellular Pathology, 2009, 31, 467-473.	0.7	0
148	Pre-Clinical Modeling of Breast Cancer: Which Model to Choose?. , 2013, , 161-175.		0
149	Abstract P1-12-12: The insulin like growth factor axis and development of tamoxifen resistance in breast cancer. , 2015, , .		0
150	The SEARCHBreast Portal: A Virtual Bioresource to Facilitate the Sharing of Surplus Animal Materials Derived from Breast Cancer Studies. Open Journal of Bioresources, 2016, 3, .	1.5	0
151	Hormone Receptors in Breast Cancer. Encyclopedia of Pathology, 2018, , 1-5.	0.0	0
152	Male Breast Cancer. Encyclopedia of Pathology, 2018, , 1-6.	0.0	0
153	Hormone Receptors in Breast Cancer. Encyclopedia of Pathology, 2020, , 161-165.	0.0	0
154	Male Breast Cancer. Encyclopedia of Pathology, 2020, , 263-268.	0.0	0
155	Obituary â€“ Margaret Wilcox. British Journal of Cancer, 2022, , .	2.9	0